Li, Wenting

Wenting Li

Analyst, Intellectual Property and Life Science

Dr. Wenting Li, an analyst in the Intellectual Property Litigation Practice, helps clients in the pharmaceutical, life sciences, chemical, and semiconductor industries at every stage of representation in complex patent cases.

Wenting provides scientific insight for intellectual property matters, drawing on her knowledge and experience as a former research chemist and patent agent. Her work on behalf of clients includes performing patent claim analyses; reviewing and interpreting technical documents; performing infringement, validity, and enforceability assessments; performing freedom to operate analyses; and assisting with post-grant proceedings.

Wenting has advised pharmaceutical, chemical, medical device, and semiconductor companies, with a focus on IP matters involving:

  • Pharmaceuticals
  • Medical devices
  • Nanotechnology
  • Materials characterization
  • Semiconductors
  • Organic electronics

Wenting offers clients an extensive background in chemistry, materials science, and medical devices, including small-molecule pharmaceuticals and biosensors. Prior to joining Latham, she was a patent agent at a leading D.C.-based boutique intellectual property law firm. She has prepared and prosecuted patent applications in a variety of industries, and has experience in the research and preparation of patentability, clearance, infringement, and validity opinions.

Wenting's experience in intellectual property matters includes advising on technical matters for:

  • A pharmaceutical company in pre-litigation analyses against competitors for infringing patents for an antibody drug
  • A pharmaceutical company in defending an inter partes review petition for a small-molecule drug
  • A pharmaceutical company in developing a large patent portfolio for a key drug candidate for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriatic arthritis*
  • A pharmaceutical company for invalidity and noninfringement opinions regarding a drug for the treatment of Parkinson’s disease*
  • A nanotechnology company for IP due diligence and client counseling regarding nanomaterials and display technology*

*Matters handled prior to joining Latham